All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
A $2 billion deal with Blackstone Group Inc. is setting Alnylam Pharmaceuticals Inc. up so that it doesn’t have worry about future equity financing and instead can concentrate on RNAi R&D.
